Description
CEP-28122 is an ALK inhibitor. It inhibits tumor growth in ALK positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroglastoma cells.
| Product Unit Size | Cost | Quantity | Stock |
|---|
CEP-28122 is an ALK inhibitor. It inhibits tumor growth in ALK positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroglastoma cells.
| Cas No. | 1022958-60-6 |
|---|---|
| Purity | ≥98% |
| Formula | C28H35ClN6O3 |
| Formula Wt. | 539.08 |
| IUPAC Name | (1S,2S,3R,4R)-3-[(5-Chloro-2-{[(7S)-1-methoxy-7-(4-morpholinyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]amino}-4-pyrimidinyl)amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide |
| Synonym | CEP 28122, CEP28122 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Cheng M., Quail M., et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther. 11(3):670-79 (2012). PMID: 22203728.
Dual mTORC1/mTORC2 inhibitor.
CID-797718 analog; potential PKD1 binding agent...
Mycotoxin produced by species of Aspergillus; D...
Allylbenzene found in spices and umbelliferous ...
Taxane synthesis intermediate.
Derivative of methyl caffeate, hydroxycinnamic ...
beta-catenin inhibitor
Endogenous opioid peptide; δOR and μOR agonis...
NSAID; TREK1 K+ potentiator, voltage-gated Na+ ...
Protein translation inhibitor, peptidyl transfe...
Immunodominant peptide epitope occurring in mul...
Endogenous peptide, produced by activation of P...
Staurosporine analog; PKC inhibitor.
NSAID; COX-1/2 and lipoxygenase inhibitor.
R-type Ca2+ and voltage-gated Na+ channel block...
MET and GSK-3α/β inhibitor.
Endogenous peptide, involved in hormone regulat...
Isoflavone, phytoestrogen found in soy; ER agon...
Endogenous glycoprotein; lactoferrin agonist.
Endogenous peptide fragment, immunostimulant; ...